[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353572-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353572-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dual-function-antibody-targeting-avb3-and-pd-l1-provide-a-promising-strategy-for-solid-tumor-therapy","Dual function antibody targeting avb3 and PD-L1 provide a promising strategy for solid tumor therapy","","The inhibition of the PD-1/PD-L1 axis has advanced cancer immunotherapy, yet monotherapy clinical efficacy remains constrained and acquired resistance is common. The integrin avb3 is linked to PD-L1 regulation and immune evasion, motivating a dual-target approach. Researchers developed the dual function antibody B1451 to recognize PD-L1 and avb3 and tested antitumor performance using preclinical in vitro and in vivo models, evaluating pathway blockade and functional antitumor effects.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dual-function-antibody-targeting-avb3-and-pd-l1-provide-a-promising-strategy-for-solid-tumor-therapy/353572/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dual-function-antibody-targeting-avb3-and-pd-l1-provide-a-promising-strategy-for-solid-tumor-therapy/353572.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are PD-1/PD-L1 monotherapies limited in solid tumors?","Question",{"text":63,"@type":64},"Clinical response rates are often low (about 10% to 30%), and many initial responders develop acquired resistance. Adverse effects can also occur due to insufficient specificity for tumor-associated lymphocytes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the role of integrin avb3 in immune evasion?",{"text":68,"@type":64},"Integrin avb3 is described as a positive regulator of PD-L1 expression and a critical contributor to cancer immune evasion, influencing sensitivity to immunotherapy.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the dual function antibody B1451 work and what did preclinical tests show?",{"text":72,"@type":64},"B1451 was engineered to bind both human PD-L1 and avb3, blocking the PD-1/PD-L1 and vitronectin/avb3 pathways. It inhibited tumor cell migration, adhesion, and angiogenesis in vitro and showed superior antitumor activity in vivo compared with monotherapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353572,1791259399,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Original Research PUBLISHED 12 January 2026  \nDOI 10.3389/fimmu.2025.1691774  \nOPEN ACCESS  \nEDITED BY  \nChristian Klein,  \nLudwig Maximilian University of Munich, Germany  \nREVIEWED BY  \nZeng Wang,  \nUniversity of Chinese Academy of Sciences, China  \nSenlian Hong,  \nPeking University, China  \n*CORRESPONDENCE  \nGenbei Wang  \n[wanggenbei@taslypharma.com](wanggenbei@taslypharma.com)[ ](wanggenbei@taslypharma.com)Ruijing Huang  \n [huangruijing5@taslypharma.com](huangruijing5@taslypharma.com)  \n†These authors have contributed equally to this work  \nRECEIVED 24 August 2025  \nREVISED 16 December 2025  \nACCEPTED 22 December 2025  \nPUBLISHED 12 January 2026  \nCITATION  \nLi G, Li W, Wang L, Bi Y, Wang Y, Zheng X, Hao R, Yin Y, Yu Y, Mu H, Li J, Ma X, Zhou S, Han J, Wang G and Huang R (2026) Dual function antibody targeting avb3  \nand PD-L1 provide a promising strategy for solid tumor therapy.  \nFront. Immunol. 16:1691774 .  \ndoi: 10.3389/fimmu.2025.1691774  \nCOPYRIGHT  \n© 2026 Li, Li, Wang, Bi, Wang, Zheng, Hao, Yin, Yu, Mu, Li, Ma, Zhou, Han, Wang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nDual function antibody targeting avb 3 and PD-L1 provide a promising strategy for solid tumor therapy  \nGuixia Li 1†, Wenlei Li 2†, Liuli Wang 1, Yuxin Bi 1, Yibo Wang 2, Xuemin Zheng 1, Ruijia Hao 1, Yanchen Yin 2, Yan Yu 2, Huaibin Mu 2, Jian Li 2, Xiaohui Ma 1, Shuiping Zhou 1, Jin Han 3, Genbei Wang 1* and Ruijing Huang 2*  \n1 Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China, 2 Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China, 3Tasly Biopharmaceuticals Co., Ltd., Tianjin, China  \nBackground: The inhibition of the PD-1/PD-L1 axis has exhibited signiﬁcant advancements in cancer immunotherapy, improving patient outcomes in various cancers. However, the clinical efﬁcacy of these monotherapies remains limited in many cases. Integrin avb3 has been identiﬁed as a positive regulator of PD-L1 expression and a critical contributor to cancer immune evasion. To address this, we developed a dual function antibody, B1451, that recognizes both PD-L1 andavb3 and evaluated its antitumor efﬁcacy in pre-clinical models in vitro and in vivo.  \nMethods: We ﬁrst analyzed the correlation between PD-L1 and avb3 expression, as well as the role of avb3 in modulating sensitivity to immunotherapy, using the TISIDB database. Subsequently, we designed and constructed a dual function PD-L1×avb3 antibody (B1451) by conjugating an integrin avb3-binding peptide to the C-terminal of the heavy chain of the anti-PD-L1 monoclonal antibody, Atezolizumab, using a (G4S)×3 linker. The antitumor efﬁcacy of B1451 was then evaluated in preclinical models in vitro and in vivo.  \nResults: Our ﬁndings demonstrated a signiﬁcant positive correlation between the gene expression of PD-L1 and avb3 across various human solid tumors . Additionally, high avb3 expression appears to inﬂuence the sensitivity to immunotherapy. The dual function antibody B1451 was capable of recognizing human PD-L1 and avb3 antigens, effectively blocking both the PD-1/PD-L1 and vitronectin/avb3 pathways. B1451 inhibited tumor cell migration, adhesion, and angiogenesis in vitro, and exhibited superior anti-tumor activity in vivo than monotherapy.  \nConclusion: The dual function antibody targeting both avb3 and PD-L1 holds the potential to reverse immune evasion and exhibit synergistic anti-tumor effects, offering a promising therapeutic strategy for the treatment of solid","cbCaim75EG4P3npO","https://ap.wps.com/l/cbCaim75EG4P3npO","pdf",13576405,16,"English","# Introduction\n## Background on PD-1/PD-L1 and limitations\n## Role of integrins and avb3 in cancer\n# Methods\n## Correlation analysis using TISIDB\n## Design of dual function antibody B1451\n## In vitro and in vivo evaluation\n# Results\n## Correlation between PD-L1 and avb3\n## Antigen recognition and pathway blockade\n## Effects on migration, adhesion, and angiogenesis\n# Conclusion","[{\"question\":\"Why are PD-1/PD-L1 monotherapies limited in solid tumors?\",\"answer\":\"Clinical response rates are often low (about 10% to 30%), and many initial responders develop acquired resistance. Adverse effects can also occur due to insufficient specificity for tumor-associated lymphocytes.\"},{\"question\":\"What is the role of integrin avb3 in immune evasion?\",\"answer\":\"Integrin avb3 is described as a positive regulator of PD-L1 expression and a critical contributor to cancer immune evasion, influencing sensitivity to immunotherapy.\"},{\"question\":\"How does the dual function antibody B1451 work and what did preclinical tests show?\",\"answer\":\"B1451 was engineered to bind both human PD-L1 and avb3, blocking the PD-1/PD-L1 and vitronectin/avb3 pathways. It inhibited tumor cell migration, adhesion, and angiogenesis in vitro and showed superior antitumor activity in vivo compared with monotherapy.\"}]","Dual function antibody targeting avb3 and PD-L1 provide a promising strategy for solid tumor therapy | PDF",1790106093,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1d5fd5cf60f2b913d5dd80881cd10d8.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cdb9d5d4fdeec9b7c23a65d4ecec85c.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c6e4c9b67045ecf7df20f65b690824f.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e9048f7ecefb208a4740eb12e11c409.webp",980,1385]